|

Sunvozertinib Clinical Trials

6 actively recruiting trials across 1 location

Also known as: DZD9008

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Dizal (Jiangsu) Pharmaceutical Co., Ltd.2
  • Tang-Du Hospital1
  • Sun Yat-sen University1
  • Sichuan University1
  • Dizal Pharmaceuticals1

Indications

  • Lung Cancer6
  • Cancer6
  • Non Small Cell Lung Cancer4
  • Mutation1
  • Lung Cancer Stage III1

Other5 trials

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
Phase 3
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Phase 2
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
Phase 2
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Phase 1/2
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
Phase 1/2

New York, New York1 trial

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.